NRX Pharmaceuticals (NRXP) Free Cash Flow (2017 - 2026)

NRX Pharmaceuticals (NRXP) has 10 years of Free Cash Flow data on file, last reported at -$4.3 million in Q1 2026.

• On a quarterly basis, Free Cash Flow fell 23.56% year-over-year to -$4.3 million in Q1 2026; TTM through Mar 2026 was -$14.9 million, a 42.83% decrease from a year earlier, with the FY2025 full-year figure at -$14.1 million, down 32.56% from the prior year.
• Free Cash Flow for Q1 2026 stood at -$4.3 million, down from -$3.7 million in the prior quarter.
• Over the last five years, Free Cash Flow for NRXP reached as high as -$2.1 million in Q4 2024 and fell as low as -$14.8 million in Q2 2022.
• Historically, Free Cash Flow has averaged -$5.3 million across 5 years, with a median of -$4.0 million in 2025.
• Across the five-year window, Free Cash Flow sank 244.38% in 2022 and soared 67.2% in 2024, its largest moves.
• Year by year, Free Cash Flow stood at -$8.3 million in 2022, then jumped by 61.63% to -$3.2 million in 2023, then soared by 34.25% to -$2.1 million in 2024, then sank by 76.41% to -$3.7 million in 2025, then retreated by 16.18% to -$4.3 million in 2026.
• Per Business Quant data, the three most recent Free Cash Flow figures were -$4.3 million in Q1 2026, -$3.7 million in Q4 2025, and -$2.9 million in Q3 2025.